Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Bamlanivimab bucks could help Lilly bounce back from a soft third quarter, but diabetes is the big focus.
The world’s largest drug companies splashed out a record $78bn on R&D last year, with Roche and Lilly the biggest spenders.
Medtronic has lined up a whole pipeline of new devices – and it will need them.